MedTrace Logo

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

NCT06118398 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2023-11-07

No results posted yet for this study

Summary

This study aims to retrospective investigate the safety and effectiveness of Efgartigimod in the acute phase of neuromyelitis optica spectrum disorders (NMOSD) patients.

Conditions

  • Neuromyelitis Optica
  • Efgartigimod

Interventions

DRUG

Intravenous methylprednisolone (IVMP) and Efgartigimod

IVMP 800-1000mg/day for 3-5 days plus Efgartigimod (Efgartigimod: 10mg/kg IV on Day 1, Day 8, Day 15 and Day 22 after IVMP.)

DRUG

IVMP

IVMP 800-1000mg/day for 3-5 days.

Sponsors & Collaborators

  • Feng Jinzhou

    lead OTHER

Principal Investigators

  • Jinzhou Feng, Ph.D · First Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-05
Primary Completion
2024-11-05
Completion
2025-05-05

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06118398 on ClinicalTrials.gov